Kura Oncology, Inc., a clinical stage biopharmaceutical company, engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company's lead drug candidate, Tipifarnib, a farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors with harvey rat sarcoma viral oncogene homolog mutations; and peripheral T-cell lymphoma. Its product pipeline also comprise preclinical programs, such as KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase to treat patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase signaling pathway; and menin-mixed lineage leukemia (MLL), a small molecule inhibitor for the treatment acute leukemias involving translocations or partial tandem duplications of the MLL gene. The company was founded in 2014 and is headquartered in La Jolla, California.
http://www.priceseries.com/trade/KURA-Kura-Oncology-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2017091220171013.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments